Stealth BioTherapeutics Our Mission

Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. Our team works with patients and advocacy organizations to better understand their journey and raise awareness of the unmet need our programs seek to address.

We collaborate with top-tier academic and medical institutions, scientific thought leaders, and clinical key opinion leaders in developing the first generation of targeted therapies focusing on mitochondrial dysfunction as it presents in these rare genetic diseases and common diseases of aging. With these collaborative efforts, we continue to advance our platform of late-stage clinical programs and novel pipeline candidates.

Innovator in Mitochondrial Therapies

Founded in 2007, Stealth BioTherapeutics is a clinical-stage biopharmaceutical company developing investigational drugs for the treatment of diseases involving mitochondrial dysfunction. Our scientific focus is on the mitochondria and on the ways in which mitochondrial therapy can positively impact the lives of patients.

Our Commitment

We are committed to positively impacting the lives of patients with novel treatment options, and to offering healthcare professionals the opportunity to transform clinical practice and patient outcomes.

Our Platform

Our compounds are being developed for mitochondrial diseases where there are no FDA-approved treatments, and where current approaches are often only palliative. Our lead candidate in development is elamipretide, an investigational drug which is formulated for both systemic and ophthalmic formulations, with the potential to modify disease through mitoprotection — the ability to preserve and restore normal energy production in mitochondria while decreasing oxidative stress.

The science underlying our lead investigational candidate is supported by independent, peer-reviewed publications and abstracts from internationally recognized congresses and symposia.